Full Press Release Details
Marshall Edwards, Inc. Announces Resignation of Stephen Breckenridge from Board of Directors and
appointment of William Rueckert as Chairman of Audit Committee
New Canaan, Connecticut December 19, 2008 Marshall Edwards, Inc. (NASDAQ: MSHL) announced that
Stephen Breckenridge resigned as a member of the Board of Directors effective December 15, 2008 for
personal reasons. Mr. Breckenridge was the Chairman of the Audit Committee and served as the audit
committee financial expert. He also served as a member of the Compensation Committee. On December
18, 2008, the Board of Directors appointed William Rueckert, an existing member of the Board, as
Chairman of the Audit Committee. The Board of Directors has determined that Mr. Rueckert qualifies
as an audit committee financial expert. As a result of Mr. Breckenridge s resignation, the size of
the Board of Directors has decreased from six to five members.
About Marshall Edwards
About Marshall Edwards, Inc. Marshall Edwards, Inc. (NASDAQ: MSHL) is a specialist oncology company
focused on the clinical development of novel anti-cancer therapeutics. These derive from a
flavonoid technology platform, which has generated a number of novel compounds characterized by
broad ranging activity against a range of cancer cell types with few side effects. The combination
of anti-tumor cell activity and low toxicity is believed to be a result of the ability of these
compounds to target an enzyme present in the cell membrane of cancer cells, thereby inhibiting the
production of pro-survival proteins within the cell. Marshall Edwards has licensed rights from
Novogen Limited (ASX: NRT NASDAQ: NVGN) to bring three oncology drugs phenoxodiol, triphendiol
and NV-143 to market globally. Marshall Edwards lead investigational drug, phenoxodiol, is in a
Phase III multinational multi-centered clinical trial for patients with recurrent ovarian cancer.
More information on the trial can be found at http://www.OVATUREtrial.com.
Marshall Edwards is majority owned by Novogen (ASX: NRT, NASDAQ: NVGN), an Australian biotechnology
company that is specializing in the development of therapeutics based on a flavonoid technology
platform. Novogen is developing a range of therapeutics across the fields of oncology,
cardiovascular disease and inflammatory diseases. More information on phenoxodiol and on the
Novogen group of companies can be found at www.marshalledwardsinc.com and www.novogen.com.
Forward Looking Statements
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and
approved by the U.S. Food and Drug Administration (the FDA ) as being safe and effective for the
intended use. Statements included in this press release that are not historical in nature are
forward-looking statements within the meaning of the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements, which are based on management s
current expectations and are subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product candidates; costs and delays in
the development and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and
the risks resulting from our dependence upon, collaboration or contractual arrangements necessary
for the development, manufacture, commercialization, marketing, sales and distribution of any
products; competitive factors; our inability to protect our patents or proprietary rights and
obtain necessary rights to third party patents and intellectual property to operate our business;
our inability to operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain market acceptance; our
inability to obtain any additional required financing; technological changes; government
regulation; changes in industry practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions to these forward-looking